Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2006-05-26
2011-11-29
Minnifield, N. M (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S184100, C424S236100, C424S237100
Reexamination Certificate
active
08067015
ABSTRACT:
The invention features methods and compositions for treatment or prevention of infection by, or disease caused by infection with, certain species of bacteria, including in particular bacteria in which a RAP-type and/or TRAP-type molecule plays a role in pathogenesis. This includesStaphylococcusspecies.
REFERENCES:
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3995651 (1976-12-01), Adams
patent: 4034756 (1977-07-01), Higuchi et al.
patent: 4111202 (1978-09-01), Theeuwes
patent: 4235871 (1980-11-01), Papahadjopoulos et al.
patent: 4320759 (1982-03-01), Theeuwes
patent: 4449983 (1984-05-01), Cortese et al.
patent: 4501728 (1985-02-01), Geho et al.
patent: 4837028 (1989-06-01), Allen
patent: 5019369 (1991-05-01), Presant et al.
patent: 5023088 (1991-06-01), Wong et al.
patent: 5049322 (1991-09-01), Devissaguet et al.
patent: 5364838 (1994-11-01), Rubsamen
patent: 6291431 (2001-09-01), Balaban et al.
patent: 6447786 (2002-09-01), Novick et al.
patent: 6475434 (2002-11-01), Darouiche
patent: 6689878 (2004-02-01), Balaban et al.
patent: 6706289 (2004-03-01), Lewis et al.
patent: 6747129 (2004-06-01), Balaban et al.
patent: 7067135 (2006-06-01), Balaban
patent: 7270969 (2007-09-01), Watt et al.
patent: 7323179 (2008-01-01), Balaban
patent: 7534857 (2009-05-01), Balaban
patent: 7824691 (2010-11-01), Balaban
patent: 2002/0090376 (2002-07-01), Kaniga et al.
patent: 2002/0102271 (2002-08-01), Balaban et al.
patent: 2004/0072748 (2004-04-01), Balaban
patent: 2004/0077534 (2004-04-01), Balaban
patent: 2006/0165716 (2006-07-01), Telford et al.
patent: 2006/0252691 (2006-11-01), Balaban
patent: 2007/0009566 (2007-01-01), Balaban
patent: 2007/0009567 (2007-01-01), Balaban
patent: 2007/0009569 (2007-01-01), Balaban
patent: 2007/0015685 (2007-01-01), Balaban
patent: 2007/0071768 (2007-03-01), Balaban
patent: 2007/0092572 (2007-04-01), Balaban et al.
patent: 2007/0092575 (2007-04-01), Balaban et al.
patent: 2007/0231335 (2007-10-01), Beutler et al.
patent: 2007/0293435 (2007-12-01), Balaban et al.
patent: 2008/0138332 (2008-06-01), Balaban
patent: 2008/0152701 (2008-06-01), Balaban
patent: 2008/0219976 (2008-09-01), Balaban
patent: 0 395 099 (1990-10-01), None
patent: 1 188 831 (2002-03-01), None
patent: 96/10579 (1996-04-01), None
patent: 97/44349 (1997-11-01), None
patent: 99/32133 (1999-07-01), None
patent: 2005/009396 (2005-02-01), None
Lowy, J. CLin. Invest., May 2003, 111/9:1265-1273.
Kiran et al, International J. Artificial Organs, Sep. 2008, 31/9:761-770 abstract only.
Balaban et al, Antimicrobial Agents and Chemotherapy.
Kiran et al, Molecular Pharmacology, 2008, 73:1578-1586.
Cirioni et al, Antimicrobial Agents and Chemotherapy, Dec. 2007, 51/12:4518-4520.
Simonetti et al, Antimicrobial Agents and Chemotherapy, Jun. 2008, 52/6:2205-2211.
Balaban et al, Int. J. Artif. Organs, 2008, 31:761-770.
International Search Report dated Dec. 10, 2008, received in International Application No. PCT/US07/82801.
Balaban et al., “Autocrine regulation of toxin synthesis byStaphylococcus aureus.” Proc. Nat'l Acad. Sci. USA92: 1619-1623 (1995).
Balaban et al., “Translation of RNAIII, theStaphylococcus aureus agrregulatory RNA molecule, can be activated by a 3′-end deletion.”FEMS Microbiol. Lett. 133: 155-161 (1995).
Balaban et al., “Autoinducer of virulence as a target for vaccine and therapy againstStaphylococcus aureus.” Science280: 438-440 (1998).
U.S. Appl. No. 11/414,350, filed May 1, 2006, Balaban.
U.S. Appl. No. 11/440,093, filed May 25, 2006, Balaban.
U.S. Appl. No. 11/441,229, filed May 26, 2006, Balaban.
Balaban et al., “Prevention of diseases caused byStaphylococcus aureususing the peptide RIP.”Peptides21: 1301-1311 (2000).
Balaban et al., “Activation and inhibition of theStaphylococcus agrsystem.”Science287: 391a (2000).
Balaban et al., “Regulation ofStaphylococcus aureuspathogenesis via target of RNAIII-activating Protein (TRAP).”J. Biol. Chem. 276: 2658-2667 (2001).
Balaban et al., “Prevention ofStaphylococcus aureusbiofilm on dialysis catheters and adherence to human cells.”Kidney Int'l63: 340-345 (2003).
Balaban et al., “Use of the quorum-sensing inhibitor RNAIII-inhibiting peptide to prevent biofilm formation in vivo by drug-resistantStaphylococcus epidermidis.” J. Infect. Dis. 187: 625-630 (2003).
Balaban et al., “A chimeric peptide composed of a dermaseptin derivative and an RNA III-inhibiting peptide prevents graft-associated infections by antibiotic-resistant staphylococci.”Antimicrob. Agents Chemother. 48: 2544-2550 (2004).
Cirioni et al., “Prophylactic efficacy of topical temporin A and RNAIII-inhibiting peptide in a subcutaneous rat pouch model of graft infection attributable to staphylococci with intermediate resistance to glycopeptides.”Circulation108: 767-771 (2003).
Costerton et al., “Bacterial biofilms: a common cause of persistent infections.”Science284: 1318-1322 (1999).
Dell'Acqua et al., “Suppression of drug-resistant staphylococcal infections by the quorum-sensing inhibitor RNAIII-inhibiting peptide.”J. Infect. Dis. 190: 318-320 (2004).
Domenico et al., “BisEDT and RIP act in synergy to prevent graft infections by resistant staphylococci.”Peptides25: 2047-2053 (2004).
Ghiselli et al., “RNAIII-inhibiting peptide and/or nisin inhibit experimental vascular graft infection with methicillin-susceptible and methicillin-resistantStaphylococcus epidermidis.” Eur. J. Vasc. Endovasc. Surg. 27: 603-607 (2004).
Giacometti et al., “RNA III inhibiting peptide inhibits in vivo biofilm formation by drug-resistantStaphylococcus aureus.” Antimicrob. Agents Chemother. 47: 1979-1983 (2003).
Giacometti et al., “RNAIII-inhibiting peptide improves efficacy of clinically used antibiotics in a murine model of staphylococcal sepsis.”Peptides26: 169-175 (2005).
Gov et al., “RNAIII inhibiting peptide (RIP), a global inhibitor ofStaphylococcus aureuspathogenesis: structure and function analysis.”Peptides22: 1609-1620 (2001).
Gov et al., “Quorum sensing in Staphylococci is regulated via phosphorylation of three conserved histidine residues.”J. Biol. Chem. 279: 14665-14672 (2004).
Hartman et al., “Quorum sensing: potential means of treating gram-negative infections?”Lancet351: 848-849 (1998).
Ji et al., “Cell density control ofStaphylococcusvirulence mediated by an octapeptide pheromone.”Proc. Nat'l Acad. Sci. USA92: 12055-12059 (1995).
Ji et al., “Bacterial interference caused by autoinducing peptide variants.”Science276: 2027-2030 (1997).
Korem et al., “Characterization of RAP, a quorum sensing activator ofStaphylococcus aureus.” FEMS Microbiol. Lett. 223: 167-175 (2003).
Korem et al., “Transcriptional profiling of target of RNAIII-activating protein, a master regulator of staphylococcal virulence.”Infect. Immun. 73: 6220-6228 (2005).
Lee, “An experimental vaccine that targets staphylococcal virulence.”Trends Micrbiol. 6: 461-463 (1998).
Mayville et al., “Structure-activity analysis of synthetic autoinducing thiolactone peptides fromStaphylococcus aureusresponsible for virulence.”Proc. Nat'l Acad. Sci. USA96: 1218-1223 (1999).
Morfeldt et al., “Activation of alpha-toxin translation inStaphylococcus aureusby thetrans-encoded antisense RNA, RNAIII.”EMBO J. 14(18): 4569-4577 (1995).
Novick et al., “Synthesis of staphylococcal virulence factors is controlled by a regulatory RNA molecule.”EMBO J. 12(120): 3967-3975 (1993).
Novick et al., “Virulence gene regulation by peptides in staphylococci and other Gram-positive bacteria.”Curr. Opin. Microbiol. 2: 40-45 (1999).
Otto, “Quorum-sensing control in Staphylococci—a target for antimicrobial drug therapy?”FEMS Microbiol. Lett. 241: 135-141 (2004).
Panlilio et al., “Methicillin-resistantStaphylococcus aureusin U.S. hospitals, 1975-1
DLA Piper (LLP) US
Minnifield N. M
LandOfFree
Methods and compositions for the treatment and prevention of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the treatment and prevention of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the treatment and prevention of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4312076